Table 1.
The baseline characteristics of patients with glioblastoma (GBM) in this study.
| Parameter | Training cohort | Validation cohort 1 | Validation cohort 2 |
|---|---|---|---|
| Dataset | TCGA | CGGA | CGGA |
| Platform | Illumina | Illumina | Agilent |
| Gender | |||
| Female | 57 (35.62%) | 100 (38.45%) | 39 (41.49%) |
| Male | 103 (64.38%) | 160 (61.54%) | 55 (58.51%) |
| Age | |||
| <50 | 36 (22.50%) | 114 (43.85%) | 44 (46.81%) |
| ≥50 | 124 (77.50%) | 146 (56.15%) | 50 (53.19%) |
| KPS | |||
| ≤70 | 34 (21.25%) | NA | NA |
| >70 | 87 (54.38%) | NA | NA |
| NA | 39 (24.37%) | 260 (100%) | 94 (100%) |
| PRS_type | |||
| Primary | 147 (91.88%) | 162 (62.31%) | 86 (91.49%) |
| Recurrent | 13 (8.12%) | 98 (37.69%) | 8 (8.51%) |
| Subtype | |||
| Mesenchymal | NA | NA | 59 (62.77%) |
| Non-Mesenchymal | NA | NA | 35 (37.23%) |
| NA | 160 (100%) | 260 (100%) | NA |
| Radiotherapy | |||
| No | 15 (9.38%) | 25 (9.62%) | 10 (10.64%) |
| Yes | 137 (85.62%) | 215 (82.69%) | 77 (81.91%) |
| NA | 8 (5.00%) | 20 (7.69%) | 7 (7.45%) |
| Chemotherapy | |||
| No | NA | 40 (15.38%) | 34 (36.17%) |
| Yes | NA | 199 (76.54%) | 55 (58.51%) |
| NA | 160 (100%) | 21 (8.08%) | 5 (5.32%) |
| Survival status | |||
| Alive | 29 (18.13%) | 46 (17.69%) | 13 (13.83%) |
| Dead | 131 (81.87%) | 214 (82.31%) | 81(86.17%) |
| Risk score | |||
| Low | 80 (50.00%) | 94 (36.15%) | 18 (19.15%) |
| High | 80 (50.00%) | 166 (63.85%) | 76 (80.85%) |
| Total | 160 (100%) | 260 (100%) | 94 (100%) |
TCGA, The Cancer Genome Atlas; CGGA, Chinese Glioma Genome Atlas; KPS, Karnofsky; NA, information not available.